Frequency of Neurological Presentations of Coronavirus Disease in Patients Presenting to a Tertiary Care Hospital During the 2019 Coronavirus Disease Pandemic

Samar Iltaf Sr. 1, Meraj Fatima 1, Salma Salman Sr. 2, Jawwad-us Salam 1, Saira Abbas 3

1. Neurology, Dow International Medical College, Dow University of Health Sciences, Karachi, PAK
2. Medicine, Dow International Medical College, Dow University of Health Sciences, Karachi, PAK
3. Neurology, Dow International Medical College, Dow University Hospital, Dow University of Health Sciences, Karachi, PAK

Corresponding author: Samar Iltaf Sr., honey.sahar79@gmail.com

Abstract

Background

Coronavirus disease 2019 (COVID-19), caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), usually presents clinically with cough, fever, shortness of breath, and loss of taste and/or smell. COVID-19 can also present with neurologic signs and symptoms, including headache, hyposmia/anosmia, encephalopathy, meningoencephalitis, Guillain-Barré syndrome, stroke, and seizure. Viral transmission occurs through aerosols generated when an infected person coughs, sneezes, or exhales and by direct touching of contaminated surfaces. The present study evaluated the frequency of neurologic presentations of coronavirus disease in patients presenting at a tertiary care hospital during the COVID-19 pandemic.

Methodology

This cross-sectional study included 350 inpatients and outpatients (self-isolated) with polymerase chain reaction-confirmed SARS-CoV-2 infection who presented at Dow International Medical College of Karachi between March and June 2020. Of these 350 patients, 68 (18.9%) presented with neurological signs and symptoms and were further evaluated. The data were analyzed statistically using IBM Statistical Product and Service Solutions (SPSS) for Windows, version 20.0 (IBM Corp., Armonk, NY).

Results

The 350 patients with SARS-CoV-2 infection included 245 (70%) men and 105 (30%) women; of these, 262 (74.9%) were married, and 88 (25.1%) were unmarried. Patients ranged in age from 17 to 88 years (mean ± standard deviation, 49.5 ± 17.4 years), with 68 (18.9%) having neurological manifestations. Headache was the most frequent neurological symptom, reported in 21 (6%) patients, followed by vertigo in 12 patients (3.4%), numbness/paresthesia in 11 (3.1%), altered level of consciousness in seven (2%), hyposmia/anosmia in five (1.4%), and encephalitis in three (0.9%). Other symptoms included sudden hemiparesis (stroke) in two patients (0.6%), flaccid paralysis due to Guillain-Barré syndrome in one (0.3%), and seizure in one (0.3%).

Conclusion

Iltaf S, Fatima M, Salman S, et al. (August 18, 2020) Frequency of Neurological Presentations of Coronavirus Disease in Patients Presenting to a Tertiary Care Hospital During the 2019 Coronavirus Disease Pandemic. Cureus 12(8): e9846. DOI 10.7759/cureus.9846
Neurological involvement is not infrequent in patients with COVID-19. Neurologic manifestations should be carefully monitored in infected patients. COVID-19 should be suspected in patients presenting with neurological abnormalities and should be included in the differential diagnosis to prevent further virus transmission.

**Categories**: Medical Education, Neurology, Infectious Disease  
**Keywords**: coronavirus disease 2019 (covid-19), polymerase chain reaction (pcr), cerebro-vascular accident (stroke), guillain-barre syndrome (gbs)

**Introduction**

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a ribonucleic acid (RNA) virus belonging to the family coronaviridae that is transmitted via respiratory aerosols, fomites, and directly from person to person. Coronavirus disease 2019 (COVID-19) was declared a worldwide pandemic by the World Health Organization on March 11, 2020 [1]. COVID-19 was first diagnosed in the city of Wuhan, China [2]. The pulmonary system is the most commonly affected, with symptoms including shortness of breath, fever, and cough the most commonly reported features. Observational studies have suggested that COVID-19 may have neurologic manifestations, including headache, nausea, vomiting, myalgia, dizziness, hyposmia/anosmia, encephalitis, and impaired consciousness (encephalopathy) [3,4]. Although the exact mechanism by which SARS-CoV-2 enters the central nervous system has not been determined, it may spread directly from the cribriform plate through the blood circulation, via mechanisms that include free radical or immune-mediated injury [4].

This study aimed to evaluate the frequency of neurologic presentations of coronavirus disease in patients presenting at a tertiary care hospital during the COVID-19 pandemic.

**Materials And Methods**

This cross-sectional study assessed the frequency of various neurological presentations of COVID-19 in patients treated for this disease at Dow University of Health Sciences (DUHS), a public sector tertiary care teaching hospital at Karachi, Pakistan, from March to June 2020. All patients, both inpatients and outpatients, who had oropharyngeal or nasopharyngeal swabs polymerase chain reaction (PCR)-positive for SARS-CoV-2, were recruited. Patients positive for immunoglobulin G antibodies to SARS-CoV-2 were excluded, as were patients with prior neurological or psychiatric diseases, systemic malignancy, hypercoagulability state, intracranial tumors, uncontrolled hypertension or diabetes mellitus, extremes of ages or anemia. The study protocol was approved by the ethics committee of the university, and all patients provided written informed consent.

A survey on neurological manifestations was specially designed for COVID-19 patients by researchers in the clinical faculty of the neurology department. This subjective survey addressed 10 neurological manifestations of COVID-19: headache, altered sensation, nausea and vomiting, sudden hemiparesis (stroke), numbness and paresthesia, vertigo, ataxia, seizure, encephalitis/meningitis, Guillain-Barré Syndrome (GBS), and myelitis. Neurological manifestations were later confirmed by a thorough review of all available patient records.

The sample size was calculated using the RaoSoft® Sample Size Calculator (RaoSoft, Inc., Seattle, WA), based on a 36.4% response distribution, a confidence interval of 95%, and a margin of error of 5%, resulting in a sample size of 550 patients. Statistical analyses were performed using IBM Statistical Product and Service Solutions (SPSS) Statistics for Windows, version 20.0. (IBM Corp., Armonk, NY). Quantitative variables were summarized as mean and standard deviation (SD) and qualitative variables as frequency and percentage. Qualitative
variables were cross-tabulated with age group and gender and compared by Chi-square tests. A p-value <0.05 was considered statistically significant.

Results

The 350 patients included 245 (70%) men and 105 (30%) women; of these, 262 (74.9%) were married, and 88 (25.1%) were unmarried. Patients ranged in age from 17 to 88 years, with a mean ± SD age of 49.5 ± 17.4 years. Overall, 68 patients (18.9%) developed neurological manifestations (Figure 1). Headache was the most common neurological symptom, observed in 21 (6%) patients, followed by vertigo in 12 (3.4%), numbness/paresthesia in 11 (3.1%), altered level of consciousness in seven (2%), hyposmia/anosmia in five (1.4%), and encephalitis in three (0.9%) (Figure 2). Other symptoms included sudden hemiparesis (stroke) in two (0.6%) patients, flaccid paralysis due to GBS in one (0.3%), and seizure in one (0.3%). No significant association was found in neurological manifestation between COVID-19 patients aged <50 years and >50 years (Table 1).
FIGURE 2: Frequency of individual neurological symptoms in COVID-19 patients.

| Clinical Symptoms                  | Patient ages | P-value |
|------------------------------------|--------------|---------|
|                                    | <50years     | >50years|
| Headache                           | Yes          | 12      | 9       | 0.124   |
|                                    | No           | 132     | 197     |         |
| Altered level of consciousness (ALOC) | Yes         | 1       | 6       | 0.145   |
|                                    | No           | 143     | 200     |         |
| Hyposmia/Anosmia                   | Yes          | 0       | 5       | 0.60    |
|                                    | No           | 144     | 201     |         |
| Sudden hemiparesis                 | Yes          | 0       | 2       | 0.236   |
|                                    | No           | 144     | 204     |         |
| Numbness/Paresthesia               | Yes          | 6       | 5       | 0.359   |
|                                    | No           | 138     | 201     |         |
| Vertigo                            | Yes          | 7       | 5       | 0.218   |
|                                    | No           | 137     | 201     |         |
| Seizure                            | Yes          | 0       | 1       | 0.402   |
|                                    | No           | 144     | 205     |         |
| Encephalitis/Meningitis            | Yes          | 0       | 3       | 0.402   |
|                                    | No           | 144     | 203     |         |
| Guillain-Barré syndrome (GBS)      | Yes          | 0       | 1       | 0.402   |
|                                    | No           | 144     | 205     |         |

TABLE 1: Neurological manifestation in COVID-19 patients aged <50 years and >50 years

Discussion

SARS-CoV-2 is the cause of the COVID-19 pandemic. Although this virus primarily affects the respiratory system, it can also cause neurological manifestations, which may be predominant or even the presenting finding in some patients. This case series reviewed the clinical and laboratory data and outcome in 350 patients, consisting of both inpatients and self-isolated...
Outpatients, who were PCR-positive for SARS-CoV-2 and were treated at Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan, from March to June 2020. Of these 350 patients, 68 (18.9%) presented with neurological manifestations. In comparison, of 214 COVID-19 patients in Wuhan, China, 78 (36.4%) had neurologic manifestation, a much higher percentage [2-5]. Our study confirmed that headache (6%), altered level of consciousness and encephalopathy (2%), hemiparesis (stroke; 0.6%), GBS (0.3%) and seizure (0.3%) were the most frequently reported neurological presentations [5,6,7,8].

**Encephalitis**

COVID-19 patients may present with neurological symptoms, including encephalitis and altered level of consciousness (encephalopathy). Genome sequencing showed that SARS-CoV-2 was present in the cerebrospinal fluid (CSF) of a Japanese patient who presented clinically with symptoms of meningoencephalitis [5]. In another case study, a woman presented with a three-day history of fever, cough, and altered mental status and was diagnosed with COVID-19 by detection of SARS-CoV-2 RNA in a nasopharyngeal swab [9]. In contrast, her CSF was negative for bacteria and viruses, and a computed tomography scan of the brain without contrast revealed symmetric bilateral hypointense signals in thalamus bilaterally, suggesting that this virus can cause encephalitis [9]. This may be due to increased expression of cytokines, including interleukin (IL)-2, IL-6, IL-7, tumor necrosis factor, granulocyte colony-stimulating factor, interferon-gamma, and free radicals associated with the severity of COVID-19.

**Anosmia/hyposmia**

Anosmia/hyposmia is one of the more common neurological manifestations of COVID-19 and may be the only presenting symptom in some patients [10]. A case study reported that a patient positive for SARS-CoV-2 presented with isolated sudden onset anosmia but no other symptoms of COVID-19 [11]. Anosmia/hyposmia presents mostly in patients in their early 20s and asymptomatic, healthy patients [12].

**Cerebrovascular disease**

The pathophysiology of hemiparesis (stroke) during for SARS-CoV-2 infection is multifactorial. Increased levels of acute-phase reactants, including leukocyte count and serum concentrations of C-reactive protein, D-dimer, ferritin, and lactate dehydrogenase, are the most common predictors of stroke. Viral infection of vascular endothelial cells accompanied by damage to the vasculature can predispose to infarct. Septicemia can predispose to coagulopathy, one of the manifestations of SARS-CoV-2 infection associated with hypercoagulability, and reduce the level of angiotensin–converting enzyme 2, resulting in tissue destruction leading to stroke [6,13]. The increased level of cytokines associated with SARS-CoV-2 infection is also the most potent cause of neuronal damage and stroke [14,15]. SARS-CoV-2 induced hypercoagulability may be the most important mechanism by which patients without any vascular risk factors develop cerebrovascular disease [16,17]. Timely diagnosis and management are vital in preventing morbidity and mortality in patients with acute stroke.

**Guillain-Barré Syndrome**

GBS is an immune-mediated demyelinating disorder to the peripheral nerves usually occurring after gastrointestinal or respiratory tract infection. Campylobacter jejuni, Zika virus, and influenza virus are the most frequent causes of GBS. Various neuromuscular disorders have been associated with COVID-19, as have other neurological disorders overlapping with GBS, such as Bickerstaff’s encephalitis [7].

**Seizure**
Seizures (generalized tonic-clonic seizures) and altered levels of consciousness have been reported in COVID-19 patients. One study of 304 patients diagnosed with COVID-19 found that only two (0.7%) had developed seizures [8]. Risk factors for mortality in COVID-19 patients who require admission to hospital have been described [18].

The mechanism underlying the development of coronavirus-associated neurological complications remains unclear. These neurological manifestations may be due to the release of pro-inflammatory cytokines that predispose to vascular endothelial injury and increase the permeability of the blood-brain barrier [5]. A recent analysis of eight studies from China that included 46,248 infected patients found that hypertension (17%), diabetes mellitus (8%), and cardiovascular diseases (5%) were the most prevalent comorbidities [18]. Moreover, coronavirus-induced hypercoagulability may be the most potent mechanism for inducing cerebrovascular disease (stroke) in patients without any vascular risk factors [16,17].

The present study had several limitations, including its retrospective design and collection of data from a single center. Laboratory and radiological investigations were not performed in all patients, as many were self-isolated. Moreover, this study did not include long-term evaluations.

Conclusions

Neurological manifestations of SARS-CoV-2-infected patients have not been documented during this pandemic. The present study evaluated the neurological manifestations of COVID-19 in patients in Karachi, Pakistan. The incidence of COVID-19 has grown dramatically around the world in recent months, and most cases are asymptomatic or mild and self-managed. Therefore, the actual numbers of cases are under-reported. The association of neurological manifestations with COVID-19 is still uncertain because many cases are also misdiagnosed as other febrile illnesses. Therefore, neurological manifestations of COVID-19 should be included in the differential diagnosis of patients with these neurological signs and symptoms. Diagnostic tests for SARS-CoV-2 should be performed in all patients with symptoms of respiratory illness and neurological symptoms.

Basic definitions and standard guidelines for research identifying the neurological manifestations of COVID-19 are warranted. Territorial, national, and global joint efforts by clinicians and researchers concentrated on high-caliber, straightforward, moral, and evidence-based exploratory practices would help push the worldwide health care network toward progress against this pandemic.

Appendices

DEPARTMENT OF Medicine

DOW university of Health Science, DIMC Karachi

COVID-19 REGISTRATION FORM

Hospital MR # _______________ Dated: _______________ Time _______________ Name _______________
s/o d/o w/o _______________ Age & Sex: _______________ NIC # _______________
Profession _______________ Home Address _______________ Contact # _______________
Travel History/Contact History

Essential Criterion

Fever or measured temperature 100.4°F of less than 14 days

With any 1 of the following

Fever

Shortness of Breath,

Flu like illness

Severe Acute Respiratory Infection (SARI), pneumonia, Acute Respiratory Distress Infection,

Sepsis and Septic Shock in a person requiring hospital admission, with no other etiology that fully explains the clinical presentation.

Neurologic clinical manifestations

· Headache

· Vertigo

· Hyposmia/Anosmia

· Altered level of consciousness

· Hemiparesis/Paraparesis

· Parasthesia/Numbness

· Encephalitis/meningitis

COVID-19 REGISTRATION FORM

___________________________                                                                 _____________________________

Name of Data Entry Operator                                                                  Name/Stamp Signature of Doctor

Additional Information
Disclosures

**Human subjects:** Consent was obtained by all participants in this study. Institutional review board was informed, issued approval Not Applicable. The institutional review board was informed about collection of data, however as no intervention was required in this study so proper documented IRB wasn’t taken. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

I would like to acknowledge the faculty of Neurology and Medicine department of Dow University of Health Sciences Ojha campus for their support in this study.

References

1. Cucinotta D, Vanelli M: WHO declares COVID-19 a pandemic. Acta Biomed. 2020, 91:157-160. 10.23750/abm.v91i1.9397
2. Velavan TP, Meyer CG: The COVID-19 epidemic. Trop Med Int Health. 2020, 25:278-280. 10.1111/tmi.15383
3. Wang D, Hu B, Hu C, et al.: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020, 325:1061-1069. 10.1001/jama.2020.1585
4. Mao L, Jin H, Wang M, et al.: Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020, 77:1-9. 10.1001/jamaneurol.2020.1127
5. Moriguchi T, Harii N, Goto J, et al.: A first case of meningitis/encephalitis associated with SARS-CoV-2. Int J Infect Dis. 2020, 94:55-58. 10.1016/j.ijid.2020.05.062
6. Hess DC, Eldahshan W, Rutkowski E: COVID-19-related stroke. Transl Stroke Res. 2020, 11:322-325. 10.1007/s12975-020-00818-9
7. Tsai L, Hsieh S, Chao C, Chen YC, Lin YH, Chang SC, Chang YC: Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol. 2004, 61:1669-1673. 10.1001/archneur.61.11.1669
8. Lu L, Xiong W, Liu D, et al.: New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: a retrospective multicenter study. Epilepsia. 2020, 61:49-53. 10.1111/epi.16524
9. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B: COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology. 2020, 201187-10. 10.1148/radiol.2020201187
10. Vaira LA, Salzano G, Deiana G, De Riu G, De Riu G: Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope. 2020, 130:1787. 10.1002/lary.28692
11. Gane SB, Kelly C, Hopkins C: Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome?. Rhinology. 2020, 58:299-301. 10.4195/Rhin20.114
12. Lao WP, Imam SA, Nguyen SA: Anosmia, hyposmia, and dysgeusia as indicators for positive SARS-CoV-2 infection. World J Otorhinolaryngol Head Neck Surg. 2020, 10.1016/j.wjorl.2020.04.001
13. Carod-Artal FJ: Neurological complications of coronavirus and COVID-19. Complicaciones neurológicas por coronavirus y COVID-19. Rev Neurol. 2020, 70:311-322. 10.33588/rn.7009.2020179
14. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S: Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
15. Manousakis G, Jensen MB, Chacon MR, Sattin JA, Levine RL: The interface between stroke and infectious disease: infectious diseases leading to stroke and infections complicating stroke. Curr Neurol Neurosci Rep. 2009, 9:28-34. 10.1007/s11910-009-0005-x

16. Avula A, Nalleballe K, Narula N, et al.: COVID-19 presenting as stroke. Brain Behav Immun. 2020, 87:115-119. 10.1016/j.bbi.2020.04.077

17. Panigada M, Bottino N, Tagliabue P, et al.: Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J ThrombHaemost. 2020, 18:1738-1742. 10.1111/jth.14850

18. Zhou F, Yu T, Du R, et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395:1054-1062. 10.1016/S0140-6736(20)30566-3